drugset
Drugs / HRS-5965
last change May 2026 re-read 2 minutes ago

HRS-5965

Small molecule

Developed for
paroxysmal nocturnal hemoglobinuria · IgA glomerulonephritis
Investigated by
Chengdu Suncadia Medicine Co., Ltd.

Trials 14 · a red edge is where a trial was stopped

today NCT07582133 · Ph 2 NCT07040787 · Ph 1 NCT07035665 · Ph 1 NCT07014826 · Ph 3 NCT06715943 · Ph 3 NCT06674915 · Ph 1 NCT06684041 · Ph 1 NCT06593938 · Ph 3 NCT06567392 · Ph 1 NCT06490991 · Ph 1 NCT06238544 · Ph 2 NCT06137768 · Ph 2 NCT06051357 · Ph 2 NCT05505955 · Ph 1
2023202420252026202720282029
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 17 trials
Phase 1 NCT07040787 Jul → Aug 2025 glomerulonephritis, hemolytic anemia Chengdu Suncadia Medicine Co., Ltd. Completed No outcome recorded
Phase 1 NCT07035665 Jun → Jul 2025 IgA glomerulonephritis, paroxysmal nocturnal hemoglobinuria Chengdu Suncadia Medicine Co., Ltd. Completed No outcome recorded
Phase 1 NCT06674915 Nov 2024 → Jan 2026 glomerular disorder Chengdu Suncadia Medicine Co., Ltd. Completed No outcome recorded
Phase 1 NCT06684041 Nov 2024 → Apr 2025 hemolytic anemia Chengdu Suncadia Medicine Co., Ltd. Completed No outcome recorded
Phase 1 NCT06567392 Sep → Oct 2024 glomerular disorder Chengdu Suncadia Medicine Co., Ltd. Completed No outcome recorded
Phase 1 NCT06490991 Jul → Aug 2024 IgA glomerulonephritis, paroxysmal nocturnal hemoglobinuria Chengdu Suncadia Medicine Co., Ltd. Completed No outcome recorded
Phase 1 NCT05505955 Oct 2022 → Nov 2023 glomerulonephritis Chengdu Suncadia Medicine Co., Ltd. Completed No outcome recorded
Phase 24 trials
Phase 2 NCT07582133 May 2026 → Jul 2029 expected IgA glomerulonephritis Chengdu Suncadia Medicine Co., Ltd. Not yet recruiting No outcome recorded
Phase 2 NCT06238544 Feb 2024 → Dec 2027 expected paroxysmal nocturnal hemoglobinuria Chengdu Suncadia Medicine Co., Ltd. Active not recruiting No outcome recorded
Phase 2 NCT06137768 Dec 2023 → Dec 2024 overdue IgA glomerulonephritis Chengdu Suncadia Medicine Co., Ltd. Active not recruiting No outcome recorded
Phase 2 NCT06051357 Nov 2023 → Mar 2024 paroxysmal nocturnal hemoglobinuria Chengdu Suncadia Medicine Co., Ltd. Completed No outcome recorded
Phase 33 trials
Phase 3 NCT07014826 Jun 2025 → Oct 2027 expected IgA glomerulonephritis Chengdu Suncadia Medicine Co., Ltd. Recruiting No outcome recorded
Phase 3 NCT06715943 Jan 2025 → Jan 2026 paroxysmal nocturnal hemoglobinuria Chengdu Suncadia Medicine Co., Ltd. Completed No outcome recorded
Phase 3 NCT06593938 Oct 2024 → Jul 2025 paroxysmal nocturnal hemoglobinuria Chengdu Suncadia Medicine Co., Ltd. Completed No outcome recorded

Evidence & citations 4 cited values

Every value below carries the sentence it was read from. 15 sources stand behind the page.

FieldValueCited text
Known as HRS-5965 ClinicalTrials.gov intervention name — accepted as the source's own label NCT06593938 ↗
13

NCT06715943 ↗

NCT06238544 ↗

NCT06674915 ↗

NCT05505955 ↗

NCT06567392 ↗

NCT06684041 ↗

NCT07014826 ↗

NCT06051357 ↗

NCT06490991 ↗

NCT07040787 ↗

NCT07582133 ↗

NCT07035665 ↗

NCT06137768 ↗
Action Inhibit “HRS-5965 is an oral selective small-molecule inhibitor of complement factor B, a key component of the alternative pathway.” PMID 40378845 ↗ May 2025
Modality Small molecule “HRS-5965 is an oral selective small-molecule inhibitor of complement factor B, a key component of the alternative pathway.” PMID 40378845 ↗ May 2025
Route Oral “HRS-5965 is an oral selective small-molecule inhibitor of complement factor B, a key component of the alternative pathway.” PMID 40378845 ↗ May 2025